肺疾患治療薬市場：薬剤クラス別、適応症別、薬剤タイプ別、流通チャネル別、エンドユーザー別-2025-2030年の世界予測

肺疾患治療薬市場は、2023年に793億5,000万米ドルと評価され、2024年には861億4,000万米ドルに達すると予測され、CAGR 8.03％で成長し、2030年には1,362億7,000万米ドルに達すると予測されています。

肺疾患治療薬市場には、喘息、COPD、肺高血圧症、肺線維症などの呼吸器疾患を治療するために設計された、幅広い医薬品と治療法が含まれます。これらの薬剤の必要性は、公害、喫煙率の増加、高齢化などの要因に起因する呼吸器疾患の世界の有病率の上昇によって強調されています。これらの治療薬には主に気管支拡張薬、コルチコステロイド、生物学的製剤が含まれ、吸入、経口、注射などさまざまな方法で投与されます。これらの疾患の効果的な管理を保証することは、患者の生活の質を高め、医療システムの全体的な経済的負担を軽減します。市場は、生物製剤、併用療法、個別化医療アプローチのイントロダクションよって大きな進歩を遂げています。主な成長要因としては、新興国における呼吸器ケア需要の増加、革新的な生物学的製剤へのシフト、呼吸器の健康を促進する政府の取り組みなどが挙げられます。最新のビジネスチャンスとしては、患者エンゲージメントとアドヒアランスのためのデジタルヘルスプラットフォームの活用、ドラッグデリバリーシステムにおけるナノテクノロジーの探求などが挙げられます。企業はデジタルヘルスプロバイダーとの提携を活用し、研究開発に投資することで優位に立つことができます。しかし、研究開発費の高騰、厳しい規制の枠組み、ジェネリック医薬品メーカーとの競合が市場成長の課題となっています。また、ヘルスケアへのアクセス格差や保険償還の問題といった制約もあります。イノベーションは、慢性呼吸器疾患をより効果的に管理するための非侵襲的デリバリー方法や新規薬剤クラスの開発に集中する可能性があります。遺伝子治療とCRISPR技術の調査により、オーダーメイドの治療ソリューションが期待できます。肺疾患治療薬市場の性質は、継続的な技術の進歩と、より効果的で的を絞った治療法の必要性によって、非常に競争が激しく、ペースが速いです。企業は、市場のポジショニングを高め、成長の可能性を獲得するために、規制状況を乗り切りながらイノベーション能力を維持することに注力すべきです。

市場力学：急速に進化する肺疾患治療薬市場の主要市場インサイトを公開

肺疾患治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肺疾患の流行と、疾患治療と医薬品入手の促進への取り組み
  • 肺疾患治療薬に関する診療報酬の改善と政府による好意的な承認
• 市場抑制要因
  • 肺疾患に使用される薬剤の回収増加
• 市場機会
  • 肺疾患治療のための新たな生物製剤および標的薬の開発
  • 吸入ドラッグデリバリー療法と技術の進歩
• 市場の課題
  • 不適切なドラッグデリバリーや薬剤耐性の発達に伴う限界

ポーターの5つの力：肺疾患治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肺疾患治療薬市場における外部からの影響の把握

外部マクロ環境要因は、肺疾患治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肺疾患治療薬市場における競合情勢の把握

肺疾患治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肺疾患治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肺疾患治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肺疾患の蔓延と疾患治療および薬剤アクセスを促進する取り組み
    • 肺疾患治療薬の償還の改善と政府の好意的な承認
  • 抑制要因
    • 肺疾患の治療に使用される薬剤の回収増加
  • 機会
    • 肺疾患治療のための新しい生物学的製剤および標的薬の開発
    • 吸入ドラッグデリバリー療法と技術の進歩
  • 課題
    • 不適切なドラッグデリバリーと薬剤耐性の発現に関連する制限
• 市場セグメンテーション分析
  • 薬物クラス：肺疾患の個別化治療を提供するための複合薬とモノクローナル抗体の製剤の進歩
  • 適応症：COPDおよび嚢胞性線維症の治療と管理に効果的な薬剤の必要性
  • 薬剤の種類：肺疾患の管理において、費用対効果の高いジェネリック医薬品が好まれる傾向
  • 流通チャネル：患者とヘルスケア提供者の間での製品浸透を高めるためのオンライン流通戦略の改善
  • エンドユーザー：病院における急性症例や重篤な呼吸器疾患に対処するための、即効性のある多様な薬剤の提供
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肺疾患治療薬市場薬剤クラス別

• 抗コリン剤
• 抗ロイコトリエン
• 抗ヒスタミン薬
• ベータ2作動薬
• 併用薬
• モノクローナル抗体
• 経口および吸入コルチコステロイド

第7章 肺疾患治療薬市場適応症別

• アレルギー性鼻炎
• 喘息
• 慢性閉塞性肺疾患
• 嚢胞性線維症
• 肺動脈高血圧

第8章 肺疾患治療薬市場薬の種類別

• ジェネリック医薬品
• 処方薬

第9章 肺疾患治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 肺疾患治療薬市場：エンドユーザー別

• ホームケア
• 病院
• 専門クリニック

第11章 南北アメリカの肺疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の肺疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの肺疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ブリッジ・バイオセラピューティクス、特発性肺線維症におけるBBT-877第2a相試験について独立データモニタリング委員会から肯定的な勧告を受けたと発表
  • ブリストルマイヤーズスクイブ、進行性肺線維症に対する治験中のLPA1拮抗薬が米国FDAの画期的治療薬に指定されたことを発表
  • 喘息に特化した資金調達が加速する中、Aiolos Bioが2億4,500万米ドルを調達して設立
  • アヴァリン、IPF吸入薬開発のため1億7,500万米ドルの資金を調達
  • ルピンはマーク・キューバンおよびCOPD財団と提携し、米国におけるCOPD治療薬へのアクセスを拡大
  • アポロ・セラピューティクス、ユニ・調査に基づく医薬品開発のため2億2,650万米ドルを調達
  • ビアトリスは、キンデバと提携し、喘息および慢性閉塞性肺疾患患者向けのシムビコートのFDA承認ジェネリック版であるブレイナ（ブデソニドおよびフォルモテロールフマル酸塩二水和物）吸入エアロゾルの発売を発表
  • 米国FDA、高齢者のRSウイルス（RSV）予防のためのファイザー社製ワクチン「ABRYSVO」を承認
  • TFFとNIEHSが呼吸器疾患用の粉末製剤の開発で提携
  • 米国FDA、高齢者向けRSウイルスワクチン「アレキシー」をGSK社が承認
  • アストラゼネカ、新しい喘息治療薬「エアスープラ」を発売
  • C4XDとアストラゼネカ、呼吸器疾患治療薬の開発で4億200万米ドルの契約を締結

企業一覧

• Pieris Pharmaceuticals, Inc.
• Amgen Inc.
• Novartis AG
• Wellona Pharma
• Icosavax, Inc.
• Grifols, S.A.
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline PLC
• Viatris Inc.
• Dr. Reddy's Laboratories Ltd.
• Sumitomo Pharma Co., Ltd.
• F. Hoffmann-La Roche AG
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A
• Vertex Pharmaceuticals Incorporated
• Verona Pharma PLC
• Johnson & Johnson Services, Inc.
• Cipla Ltd.
• Abbott Laboratories
• Lupin Pharmaceuticals, Inc.
• Mallinckrodt PLC
• United Therapeutics Corporation
• Merck & Co., Inc.
• Pfizer Inc.
• Lung Therapeutics Inc.
• Bayer AG
• Bristol Myers Squibb Company
• AstraZeneca PLC
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Gilead Sciences, Inc.
• Chiesi Farmaceutici S.p.A

LIST OF FIGURES

• FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PULMONARY DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 169. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. POLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 189. POLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. POLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. QATAR PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 194. QATAR PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. QATAR PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 241. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 242. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Pulmonary Drugs Market was valued at USD 79.35 billion in 2023, expected to reach USD 86.14 billion in 2024, and is projected to grow at a CAGR of 8.03%, to USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide array of medications and therapies designed to treat respiratory diseases such as asthma, COPD, pulmonary hypertension, and lung fibrosis. The necessity for these drugs is underscored by the rising global prevalence of respiratory disorders attributable to factors like pollution, increasing smoking rates, and a growing aging population. These therapies primarily include bronchodilators, corticosteroids, and biologics, delivered through various modes like inhalation, oral or injectable administration. Ensuring effective management of these conditions enhances patients' quality of life and reduces the overall economic burden on healthcare systems. The market has seen significant advancements with the introduction of biologics, combination therapies, and personalized medicine approaches. Key growth influencers include an increasing demand for respiratory care in emerging economies, a shift towards innovative biologic drugs, and government initiatives promoting respiratory health. The latest opportunities include leveraging digital health platforms for patient engagement and adherence, and the exploration of nanotechnology in drug delivery systems. Companies can capitalize on partnerships with digital health providers and invest in R&D to stay ahead. However, market growth is challenged by high R&D costs, stringent regulatory frameworks, and competition from generic drug manufacturers. Limitations include disparities in healthcare access and reimbursement issues. Innovation could focus on developing non-invasive delivery methods and novel drug classes to manage chronic respiratory conditions more effectively. Research into gene therapy and CRISPR technology offers prospects for tailored treatment solutions. The nature of the pulmonary drugs market is highly competitive and fast-paced, driven by continuous technological advancements and the need for more effective, targeted therapies. Companies should focus on sustaining innovation capability while navigating regulatory landscapes to enhance market positioning and capture growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pulmonary Drugs Market

The Pulmonary Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
  • Improvements in reimbursements and favorable government approvals for pulmonary drugs
• Market Restraints
  • Increasing recall of drugs used for pulmonary conditions
• Market Opportunities
  • Development of new biologics and targeted drugs for pulmonary disease treatment
  • Advancements in inhaled drug delivery therapies and technologies
• Market Challenges
  • Limitations associated with improper drug delivery and development of drug resistance

Porter's Five Forces: A Strategic Tool for Navigating the Pulmonary Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pulmonary Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pulmonary Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pulmonary Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pulmonary Drugs Market

A detailed market share analysis in the Pulmonary Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pulmonary Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pulmonary Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Pieris Pharmaceuticals, Inc., Amgen Inc., Novartis AG, Wellona Pharma, Icosavax, Inc., Grifols, S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Viatris Inc., Dr. Reddy's Laboratories Ltd., Sumitomo Pharma Co., Ltd., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., Sanofi S.A, Vertex Pharmaceuticals Incorporated, Verona Pharma PLC, Johnson & Johnson Services, Inc., Cipla Ltd., Abbott Laboratories, Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, United Therapeutics Corporation, Merck & Co., Inc., Pfizer Inc., Lung Therapeutics Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, AbbVie Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., and Chiesi Farmaceutici S.p.A.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, and Oral & Inhaled Corticosteroids.
• Based on Indication, market is studied across Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Pulmonary Arterial Hypertension.
• Based on Drug Type, market is studied across Generic Drugs and Prescription Drugs.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End-User, market is studied across Homecare, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
    • 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
  • 5.1.2. Restraints
    • 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
    • 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
  • 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
  • 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
  • 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
  • 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pulmonary Drugs Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-Cholinergic Agents
• 6.3. Anti-Leukotrienes
• 6.4. Antihistamines
• 6.5. Beta-2 Agonists
• 6.6. Combination Drugs
• 6.7. Monoclonal Antibodies
• 6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

• 7.1. Introduction
• 7.2. Allergic Rhinitis
• 7.3. Asthma
• 7.4. Chronic Obstructive Pulmonary Disease
• 7.5. Cystic Fibrosis
• 7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Generic Drugs
• 8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
  • 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
  • 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
  • 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
  • 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
  • 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
  • 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
  • 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
  • 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
  • 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
  • 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
  • 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

Companies Mentioned

• 1. Pieris Pharmaceuticals, Inc.
• 2. Amgen Inc.
• 3. Novartis AG
• 4. Wellona Pharma
• 5. Icosavax, Inc.
• 6. Grifols, S.A.
• 7. Teva Pharmaceutical Industries Ltd.
• 8. GlaxoSmithKline PLC
• 9. Viatris Inc.
• 10. Dr. Reddy's Laboratories Ltd.
• 11. Sumitomo Pharma Co., Ltd.
• 12. F. Hoffmann-La Roche AG
• 13. Sun Pharmaceutical Industries Ltd.
• 14. Sanofi S.A
• 15. Vertex Pharmaceuticals Incorporated
• 16. Verona Pharma PLC
• 17. Johnson & Johnson Services, Inc.
• 18. Cipla Ltd.
• 19. Abbott Laboratories
• 20. Lupin Pharmaceuticals, Inc.
• 21. Mallinckrodt PLC
• 22. United Therapeutics Corporation
• 23. Merck & Co., Inc.
• 24. Pfizer Inc.
• 25. Lung Therapeutics Inc.
• 26. Bayer AG
• 27. Bristol Myers Squibb Company
• 28. AstraZeneca PLC
• 29. AbbVie Inc.
• 30. Boehringer Ingelheim International GmbH
• 31. Gilead Sciences, Inc.
• 32. Chiesi Farmaceutici S.p.A